Published in Expert Opin Ther Targets on February 01, 2006
Large-scale structural analysis of the classical human protein tyrosine phosphatome. Cell (2009) 3.51
LYP inhibits T-cell activation when dissociated from CSK. Nat Chem Biol (2012) 1.37
Targeting protein tyrosine phosphatases for anticancer drug discovery. Curr Pharm Des (2010) 1.10
Inhibitors of Src homology-2 domain containing protein tyrosine phosphatase-2 (Shp2) based on oxindole scaffolds. J Med Chem (2008) 1.03
Crystal structures and inhibitor identification for PTPN5, PTPRR and PTPN7: a family of human MAPK-specific protein tyrosine phosphatases. Biochem J (2006) 1.00
Multidentate small-molecule inhibitors of vaccinia H1-related (VHR) phosphatase decrease proliferation of cervix cancer cells. J Med Chem (2009) 0.94
Reduced expression of CD45 protein-tyrosine phosphatase provides protection against anthrax pathogenesis. J Biol Chem (2009) 0.94
Inhibition of lymphoid tyrosine phosphatase by benzofuran salicylic acids. J Med Chem (2010) 0.94
In silico screening for PTPN22 inhibitors: active hits from an inactive phosphatase conformation. ChemMedChem (2009) 0.94
Protein tyrosine phosphatase expression profile of rheumatoid arthritis fibroblast-like synoviocytes: a novel role of SH2 domain-containing phosphatase 2 as a modulator of invasion and survival. Arthritis Rheum (2013) 0.92
Is Cdc25 a druggable target? Anticancer Agents Med Chem (2008) 0.89
Development of molecular probes for second-site screening and design of protein tyrosine phosphatase inhibitors. J Med Chem (2007) 0.89
NMR-based design and evaluation of novel bidentate inhibitors of the protein tyrosine phosphatase YopH. Chem Biol Drug Des (2010) 0.88
Tissue-specific alterations of PRL-1 and PRL-2 expression in cancer. Am J Transl Res (2012) 0.86
High-throughput screen using a single-cell tyrosine phosphatase assay reveals biologically active inhibitors of tyrosine phosphatase CD45. Proc Natl Acad Sci U S A (2012) 0.86
CuAAC click chemistry accelerates the discovery of novel chemical scaffolds as promising protein tyrosine phosphatases inhibitors. Curr Med Chem (2012) 0.84
Generation of inhibitor-sensitive protein tyrosine phosphatases via active-site mutations. Methods (2007) 0.84
Toward a molecular understanding of the interaction of dual specificity phosphatases with substrates: insights from structure-based modeling and high throughput screening. Curr Med Chem (2008) 0.83
Small molecule inhibitors of SHP2 tyrosine phosphatase discovered by virtual screening. Bioorg Med Chem Lett (2011) 0.82
Identification of small molecule inhibitors of PTPσ through an integrative virtual and biochemical approach. PLoS One (2012) 0.80
Inhibition of hematopoietic protein tyrosine phosphatase augments and prolongs ERK1/2 and p38 activation. ACS Chem Biol (2011) 0.78
Integrating virtual and biochemical screening for protein tyrosine phosphatase inhibitor discovery. Methods (2013) 0.78
Visualizing active-site dynamics in single crystals of HePTP: opening of the WPD loop involves coordinated movement of the E loop. J Mol Biol (2010) 0.77
Knowledge-based characterization of similarity relationships in the human protein-tyrosine phosphatase family for rational inhibitor design. J Med Chem (2009) 0.77
Distinct functional and conformational states of the human lymphoid tyrosine phosphatase catalytic domain can be targeted by choice of the inhibitor chemotype. J Comput Aided Mol Des (2011) 0.76
Identification of novel, less toxic PTP-LAR inhibitors using in silico strategies: pharmacophore modeling, SADMET-based virtual screening and docking. J Mol Model (2011) 0.76
Analysis of the Protein phosphotome of Entamoeba histolytica reveals an intricate phosphorylation network. PLoS One (2013) 0.76
High-Throughput Screening (HTS) by NMR Guided Identification of Novel Agents Targeting the Protein Docking Domain of YopH. ChemMedChem (2015) 0.75
Perspective: Tyrosine phosphatases as novel targets for antiplatelet therapy. Bioorg Med Chem (2015) 0.75
Nitropropenyl benzodioxole, an anti-infective agent with action as a protein tyrosine phosphatase inhibitor. Open Med Chem J (2014) 0.75
A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet (2004) 12.25
Protein tyrosine phosphatases in the human genome. Cell (2004) 8.09
Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat Genet (2005) 6.48
Role of PTPN22 in type 1 diabetes and other autoimmune diseases. Semin Immunol (2006) 2.79
Apoptosis-based therapies for hematologic malignancies. Blood (2005) 2.77
Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. J Med Chem (2003) 2.64
Cancer prevention by tea polyphenols is linked to their direct inhibition of antiapoptotic Bcl-2-family proteins. Cancer Res (2003) 2.43
Apoptosis-inducing factor triggered by poly(ADP-ribose) polymerase and Bid mediates neuronal cell death after oxygen-glucose deprivation and focal cerebral ischemia. J Neurosci (2005) 2.32
Identification of a new JNK inhibitor targeting the JNK-JIP interaction site. Proc Natl Acad Sci U S A (2008) 2.26
Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-X(L). Chem Biol (2004) 2.03
Multi-walled carbon nanotubes induce T lymphocyte apoptosis. Toxicol Lett (2005) 1.94
Protein tyrosine phosphatases in autoimmunity. Annu Rev Immunol (2008) 1.90
Cooperative phosphorylation of the tumor suppressor phosphatase and tensin homologue (PTEN) by casein kinases and glycogen synthase kinase 3beta. J Biol Chem (2005) 1.75
A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition. Cell Stem Cell (2013) 1.59
SUMO1 modification of PTEN regulates tumorigenesis by controlling its association with the plasma membrane. Nat Commun (2012) 1.58
PTEN regulation by Akt-EGR1-ARF-PTEN axis. EMBO J (2008) 1.58
Aurothiomalate inhibits transformed growth by targeting the PB1 domain of protein kinase Ciota. J Biol Chem (2006) 1.55
Systems-based design of bi-ligand inhibitors of oxidoreductases: filling the chemical proteomic toolbox. Chem Biol (2004) 1.52
Role of excitatory amino acid transporter-2 (EAAT2) and glutamate in neurodegeneration: opportunities for developing novel therapeutics. J Cell Physiol (2011) 1.50
Targeting Mcl-1 for the therapy of cancer. Expert Opin Investig Drugs (2011) 1.39
LYP inhibits T-cell activation when dissociated from CSK. Nat Chem Biol (2012) 1.37
Lck dephosphorylation at Tyr-394 and inhibition of T cell antigen receptor signaling by Yersinia phosphatase YopH. J Biol Chem (2003) 1.34
Targeting the Bcl-2 family for cancer therapy. Expert Opin Ther Targets (2012) 1.33
Efficient synthetic inhibitors of anthrax lethal factor. Proc Natl Acad Sci U S A (2005) 1.32
Loss of the VHR dual-specific phosphatase causes cell-cycle arrest and senescence. Nat Cell Biol (2006) 1.31
Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity. Proc Natl Acad Sci U S A (2011) 1.31
Protein tyrosine phosphatase PTPN22 in human autoimmunity. Autoimmunity (2007) 1.28
Anthrax lethal factor protease inhibitors: synthesis, SAR, and structure-based 3D QSAR studies. J Med Chem (2006) 1.27
Inhibition of Yersinia tyrosine phosphatase by furanyl salicylate compounds. J Biol Chem (2004) 1.26
Full-length single-walled carbon nanotubes decorated with streptavidin-conjugated quantum dots as multivalent intracellular fluorescent nanoprobes. Biomacromolecules (2006) 1.26
The solution structure of the bacterial HSP70 chaperone protein domain DnaK(393-507) in complex with the peptide NRLLLTG. Protein Sci (2003) 1.24
Structural analysis of Siah1-Siah-interacting protein interactions and insights into the assembly of an E3 ligase multiprotein complex. J Biol Chem (2005) 1.23
Negative feedback regulation of the tumor suppressor PTEN by phosphoinositide-induced serine phosphorylation. J Immunol (2002) 1.23
BI-97C1, an optically pure Apogossypol derivative as pan-active inhibitor of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. J Med Chem (2010) 1.23
TCR- and CD28-mediated recruitment of phosphodiesterase 4 to lipid rafts potentiates TCR signaling. J Immunol (2004) 1.23
Differential phosphorylation of NG2 proteoglycan by ERK and PKCalpha helps balance cell proliferation and migration. J Cell Biol (2007) 1.22
Targeting apoptosis via chemical design: inhibition of bid-induced cell death by small organic molecules. Chem Biol (2004) 1.21
Control of vesicle fusion by a tyrosine phosphatase. Nat Cell Biol (2004) 1.21
Haematopoietic protein tyrosine phosphatase (HePTP) phosphorylation by cAMP-dependent protein kinase in T-cells: dynamics and subcellular location. Biochem J (2004) 1.20
KCTD5, a putative substrate adaptor for cullin3 ubiquitin ligases. FEBS J (2008) 1.18
Mechanism by which Mcl-1 regulates cancer-specific apoptosis triggered by mda-7/IL-24, an IL-10-related cytokine. Cancer Res (2010) 1.18
Tyrosine phosphorylation of VHR phosphatase by ZAP-70. Nat Immunol (2002) 1.16
Inhibition of T cell antigen receptor signaling by VHR-related MKPX (VHX), a new dual specificity phosphatase related to VH1 related (VHR). J Biol Chem (2001) 1.14
Structure-activity relationships by interligand NOE-based design and synthesis of antiapoptotic compounds targeting Bid. Proc Natl Acad Sci U S A (2006) 1.13
Aurintricarboxylic acid blocks in vitro and in vivo activity of YopH, an essential virulent factor of Yersinia pestis, the agent of plague. J Biol Chem (2003) 1.13
Inhibition of Siah2 ubiquitin ligase by vitamin K3 (menadione) attenuates hypoxia and MAPK signaling and blocks melanoma tumorigenesis. Pigment Cell Melanoma Res (2009) 1.12
Apogossypol derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. J Med Chem (2009) 1.11
Regulation of the ring finger E3 ligase Siah2 by p38 MAPK. J Biol Chem (2006) 1.11
Apogossypol derivatives as antagonists of antiapoptotic Bcl-2 family proteins. Mol Cancer Ther (2009) 1.11
Phosphorylation of NG2 proteoglycan by protein kinase C-alpha regulates polarized membrane distribution and cell motility. J Biol Chem (2004) 1.11
Identification of small molecules that sensitize resistant tumor cells to tumor necrosis factor-family death receptors. Cancer Res (2006) 1.11
Strategies for developing protein tyrosine phosphatase inhibitors. Methods (2007) 1.10
Arginine methylation of STAT1 regulates its dephosphorylation by T cell protein tyrosine phosphatase. J Biol Chem (2002) 1.10
Development of paramagnetic probes for molecular recognition studies in protein kinases. J Med Chem (2008) 1.09
A conserved mechanism for control of human and mouse embryonic stem cell pluripotency and differentiation by shp2 tyrosine phosphatase. PLoS One (2009) 1.08
Targeting host cell furin proprotein convertases as a therapeutic strategy against bacterial toxins and viral pathogens. J Biol Chem (2007) 1.08
Novel MT1-MMP small-molecule inhibitors based on insights into hemopexin domain function in tumor growth. Cancer Res (2012) 1.08
SKAP55 modulates T cell antigen receptor-induced activation of the Ras-Erk-AP1 pathway by binding RasGRP1. Mol Immunol (2007) 1.07
Functional specialization in proline biosynthesis of melanoma. PLoS One (2012) 1.06
Cutting edge: selective tyrosine dephosphorylation of interferon-activated nuclear STAT5 by the VHR phosphatase. J Immunol (2007) 1.05
Activation of ZAP-70 through specific dephosphorylation at the inhibitory Tyr-292 by the low molecular weight phosphotyrosine phosphatase (LMPTP). J Biol Chem (2002) 1.05
A high-throughput screening approach to anthrax lethal factor inhibition. Bioorg Chem (2007) 1.05
SAR by ILOEs: an NMR-based approach to reverse chemical genetics. Chemistry (2006) 1.04
Cervix carcinoma is associated with an up-regulation and nuclear localization of the dual-specificity protein phosphatase VHR. BMC Cancer (2008) 1.04
Ubiquitin ligase substrate identification through quantitative proteomics at both the protein and peptide levels. J Biol Chem (2011) 1.04
Knockdown of C-terminal Src kinase by siRNA-mediated RNA interference augments T cell receptor signaling in mature T cells. Eur J Immunol (2004) 1.04
Low-molecular-weight protein tyrosine phosphatase and human disease: in search of biochemical mechanisms. Arch Immunol Ther Exp (Warsz) (2002) 1.03
MDA-9/syntenin and IGFBP-2 promote angiogenesis in human melanoma. Cancer Res (2012) 1.03
Chelator fragment libraries for targeting metalloproteinases. ChemMedChem (2010) 1.02
The lipid-binding SEC14 domain. Biochim Biophys Acta (2007) 1.02
Low-molecular-weight protein tyrosine phosphatases of Bacillus subtilis. J Bacteriol (2005) 1.01
A disalicylic acid-furanyl derivative inhibits ephrin binding to a subset of Eph receptors. Chem Biol Drug Des (2011) 1.01
An optically pure apogossypolone derivative as potent pan-active inhibitor of anti-apoptotic bcl-2 family proteins. Front Oncol (2011) 1.01
Structure- and fragment-based approaches to protease inhibition. Curr Top Med Chem (2006) 1.01
NMR-based techniques in the hit identification and optimisation processes. Expert Opin Ther Targets (2004) 1.00
HTS by NMR of combinatorial libraries: a fragment-based approach to ligand discovery. Chem Biol (2013) 1.00
Dispersion of pristine single-walled carbon nanotubes in water by a thiolated organosilane: application in supramolecular nanoassemblies. J Phys Chem B (2006) 1.00
Covalent decoration of multi-walled carbon nanotubes with silica nanoparticles. Chem Commun (Camb) (2004) 1.00
Novel targeted system to deliver chemotherapeutic drugs to EphA2-expressing cancer cells. J Med Chem (2012) 1.00
Synthesis and evaluation of Apogossypol atropisomers as potential Bcl-xL antagonists. Cancer Lett (2008) 1.00
The minimal essential core of a cysteine-based protein-tyrosine phosphatase revealed by a novel 16-kDa VH1-like phosphatase, VHZ. J Biol Chem (2004) 1.00
In vitro characterization of the Bacillus subtilis protein tyrosine phosphatase YwqE. J Bacteriol (2005) 0.99
Virtual docking approaches to protein kinase B inhibition. J Med Chem (2005) 0.98
SAR by interligand nuclear overhauser effects (ILOEs) based discovery of acylsulfonamide compounds active against Bcl-x(L) and Mcl-1. J Med Chem (2011) 0.98
NMR studies of a heterotypic Sam-Sam domain association: the interaction between the lipid phosphatase Ship2 and the EphA2 receptor. Biochemistry (2008) 0.98
BI-69A11-mediated inhibition of AKT leads to effective regression of xenograft melanoma. Pigment Cell Melanoma Res (2009) 0.98
Regulation of MAP kinases by the VHR dual-specific phosphatase: implications for cell growth and differentiation. Cell Cycle (2006) 0.98
A fragment-based approach for the discovery of isoform-specific p38alpha inhibitors. ACS Chem Biol (2007) 0.98
Design, synthesis, and structure-activity relationship of substrate competitive, selective, and in vivo active triazole and thiadiazole inhibitors of the c-Jun N-terminal kinase. J Med Chem (2009) 0.98
Enhanced delivery of mda-7/IL-24 using a serotype chimeric adenovirus (Ad.5/3) in combination with the Apogossypol derivative BI-97C1 (Sabutoclax) improves therapeutic efficacy in low CAR colorectal cancer cells. J Cell Physiol (2012) 0.97
Removal of C-terminal SRC kinase from the immune synapse by a new binding protein. Mol Cell Biol (2005) 0.97
Targeted delivery of paclitaxel to EphA2-expressing cancer cells. Clin Cancer Res (2012) 0.96
Enlargement of secretory vesicles by protein tyrosine phosphatase PTP-MEG2 in rat basophilic leukemia mast cells and Jurkat T cells. J Immunol (2002) 0.96